ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-07-09

Prespecified interim analysis of 639 adults with previously treated CLL/SLL: adding pirtobrutinib to fixed-duration venetoclax-rituximab improved progression-free survival vs venetoclax-rituximab (HR 0·547; 24-month PFS 87% vs 72%). Grade ≥3 adverse events 79% vs 73%.

RCTn = 639
Davids et al. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.